HCPCS Code P9070: A Complete Guide to Billing for Blood Products and Transfusions

The ability to transfuse blood and blood products is one of the most fundamental and life-saving interventions in modern medicine. From trauma patients experiencing massive hemorrhage to oncology patients requiring supportive care, the availability of safe blood is critical. While the act of transfusing blood is a medical procedure, the blood product itself is a billable supply.

In the HCPCS Level II coding system, “P” codes are designated for “Pathology and Laboratory Services.” This category includes a range of services, but it is most notably used to bill for blood and blood products. HCPCS code P9070 is a specific code that appears frequently on both inpatient and outpatient claims.

Understanding how to correctly bill for P9070 is essential for hospital billing departments, blood banks, and infusion centers. This guide will break down the code, explain when it is used, and clarify the complex rules around transfusion billing.

What is HCPCS Code P9070?

The P-series of HCPCS codes is reserved for laboratory services that are not easily described by a CPT code, most notably the collection, processing, and supply of blood products. These codes represent the cost of the product itself, not the nursing time or equipment used to infuse it.

The official description for HCPCS code P9070 is: “Plasma, pooled, pathogen reduced, per 200 ml.”

Let’s dissect this specific description to understand what product this code represents:

• Plasma: This is the liquid component of blood. It is the straw-colored fluid that remains after red blood cells, white blood cells, and platelets are removed. Plasma contains water, electrolytes, proteins (like albumin and clotting factors), hormones, and waste products.

• Pooled: This is a critical term. It means that the plasma unit was created by combining (“pooling”) plasma donations from multiple donors. This is in contrast to a “single-donor” or “apheresis” plasma unit. Pooling ensures a larger volume and a more standardized concentration of components, but it also exposes the recipient to multiple donors.

• Pathogen Reduced: This refers to a specific treatment process applied to the plasma after collection. The plasma is treated with a chemical or light-based process (e.g., solvent/detergent treatment or riboflavin/UV light) to inactivate potential viruses, bacteria, and parasites. This is a safety measure designed to reduce the risk of transfusion-transmitted infections.

• Per 200 ml: This is the unit of measure for billing. One unit of P9070 equals 200 milliliters of this specially processed pooled plasma.

In simple terms, P9070 is the code used to bill for a bag of highly processed, purified, and virus-inactivated plasma that has been derived from a large pool of blood donors.

The Clinical Context: Why is P9070 Used?

Plasma transfusions are not given for routine fluid replacement. They are given for specific medical indications where the patient needs the proteins and clotting factors found in plasma. Pathogen-reduced pooled plasma is often preferred in many settings due to its enhanced safety profile.

Here are the most common reasons a physician might order the product represented by P9070:

1. Coagulopathy and Bleeding

This is the primary indication. Plasma contains all the clotting factors necessary for blood to clot. Patients with severe liver disease, those on warfarin (a blood thinner) who are actively bleeding, or those experiencing Disseminated Intravascular Coagulation (DIC) often require urgent plasma transfusions to stop or prevent life-threatening hemorrhage.

2. Massive Transfusion Protocols (MTP)

In trauma situations where a patient is losing large volumes of blood, they are not just losing red blood cells; they are losing clotting factors and plasma volume. Hospitals use “Massive Transfusion Protocols” that provide a balanced ratio of blood components—including red blood cells, plasma, and platelets—to mimic whole blood and prevent dilutional coagulopathy.

3. Thrombotic Thrombocytopenic Purpura (TTP)

TTP is a rare, life-threatening disorder that causes blood clots to form in small blood vessels throughout the body. The standard treatment is therapeutic plasma exchange (TPE), a procedure that removes the patient’s plasma and replaces it with donor plasma. Pathogen-reduced plasma is commonly used for this indication.

4. Warfarin Reversal (in emergencies)

Before the widespread availability of Prothrombin Complex Concentrates (PCCs), plasma was the standard treatment for reversing the effects of warfarin in a patient with a life-threatening bleed (like an intracranial hemorrhage). Plasma is still used when PCCs are contraindicated or unavailable.

Billing for P9070: The Inpatient and Outpatient Divide

The way you bill for P9070 depends entirely on the patient’s status: inpatient or outpatient. This is a common source of confusion, so we will clarify it here.

1. The Outpatient Setting (OPPS)

In a hospital’s outpatient department, emergency room, or an ambulatory infusion center, the billing is itemized. The claim will list the services and products provided.

• You would bill P9070 for the plasma product.

• You would bill a CPT code for the administration service (e.g., 36430 for a transfusion).

• You might bill other HCPCS codes for red blood cells (e.g., P9021) if those were also given.

Payment Rule: Under the Hospital Outpatient Prospective Payment System (OPPS), many blood products, including plasma, are “packaged.” This means their cost is bundled into the payment for the primary service (the emergency room visit or the infusion clinic visit). The hospital does not usually receive a separate, additional payment for P9070 in the outpatient setting, although it must still be coded to account for costs.

2. The Inpatient Setting (IPPS)

When a patient is admitted to the hospital, the billing system changes dramatically. The claim is submitted using a uniform bill (UB-04), but the reimbursement is based on a single Diagnosis-Related Group (DRG) payment, not individual charges.

• You would still charge for the plasma on the patient’s itemized bill using P9070 to track utilization and costs.

• However, the payer (like Medicare) does not pay “per unit” of plasma. The cost of the plasma is a factor in the overall cost of the patient’s care, which influences the hospital’s overall DRG payment. The hospital receives one lump sum for the entire admission, not a separate check for the blood products used.

3. Critical Access Hospitals (CAHs)

Critical Access Hospitals are a special designation for rural facilities. They often receive cost-based reimbursement. For CAHs, accurate coding of all supplies, including P9070, is crucial because their reimbursement is directly tied to their reported costs. Tracking every unit of plasma with the correct code directly impacts their bottom line.

The Crucial Role of the Modifier: CR and JG

When billing for blood products, especially in response to a disaster or a specific program, modifiers become essential.

• CR Modifier (Catastrophe/Disaster Related): This modifier is used when a service is related to a specific declared disaster. It helps track costs associated with the disaster response and may have special reimbursement implications.

• JG Modifier (Drug or Biological acquired with 340B Drug Pricing Program): If the hospital acquired the plasma (or any drug) through the 340B Program, which provides discounted prices to safety-net providers, they may be required to report this using the JG modifier. This is critical for program compliance.

Documentation: Connecting the Need to the Product

Like all medical billing, the key to getting a claim paid (or passing an audit) is documentation that proves medical necessity. The physician’s order and the clinical notes must clearly support the need for a plasma transfusion.

The documentation must show:

1. A Clear Diagnosis: An ICD-10-CM code that supports the need for plasma. For example:

   • D65 (Disseminated intravascular coagulation)

   • K72.00 (Acute and subacute hepatic failure without coma)

   • T45.515A (Adverse effect of anticoagulants, initial encounter)

2. Clinical Justification: The physician’s progress notes should explain why the patient needs plasma. “Patient has active bleeding with an INR of 8.0. Order 2 units of plasma for urgent reversal.”

3. Laboratory Values: Supporting lab results, such as an elevated International Normalized Ratio (INR) or Prothrombin Time (PT), are strong evidence for medical necessity.

4. Product Administration Record: The nursing notes must document the type of product, the volume infused, the start and stop times, and any transfusion reactions.

Important Note: While P9070 is for pathogen reduced plasma, you must verify that the specific product your blood bank provided matches this description. If you used standard Fresh Frozen Plasma (FFP), the code might be P9017 (Plasma, frozen, single donor). If you used Plasma Frozen Within 24 Hours (PF24), the code might be P9059. Always check the product label from the blood bank to ensure you are using the correct code.

How Many Units of P9070 Should Be Billed?

The billing unit for P9070 is 200 ml. However, the actual plasma bags provided by a blood bank are often not exactly 200 ml. Standard plasma units can range from 180 ml to 300 ml, depending on the donor and the pooling process.

The standard billing practice is to bill 1 unit of P9070 per bag of plasma administered, as long as the bag is approximately 200 ml. Unlike drug codes (like J-codes) where you calculate based on mg, blood products are generally billed per “bag” or “unit” issued by the blood bank, with the understanding that the HCPCS code descriptor represents a standard volume.

What if the patient is a child?
In pediatrics, a full adult unit of plasma is rarely given. The blood bank might split a single unit into smaller aliquots (e.g., 50 ml syringes). In this case, you still bill based on the units issued by the blood bank. If a single unit of plasma is split into four aliquots for a neonate over two days, you would likely bill 1 unit on the first day and the remaining aliquots as they are used, tracking back to the original bag to avoid billing for more product than was actually consumed from the donor supply.

Common Billing Errors and Pitfalls

Accurate billing for blood products is often audited. Here are the most common mistakes to avoid:

The Financial Impact of Blood Product Billing

Blood products are a massive budget item for any hospital. Plasma, especially pathogen-reduced plasma, is expensive. The cost includes not only the plasma itself but also the extensive testing, processing, storage, and transportation required to ensure it is safe and available.

For a hospital operating under the inpatient DRG system, a patient who requires 10 units of plasma due to a liver transplant has a significantly higher cost of care than a patient with the same DRG who requires no plasma. While the hospital may not be paid “per unit,” the overall utilization of blood products influences the DRG weight calculations over time and impacts contract negotiations with payers.

In the outpatient setting, although the plasma is often packaged into the visit payment, accurate coding is necessary for the hospital to track its true costs and to identify opportunities for process improvement or cost savings.

Conclusion

HCPCS code P9070 represents a specific, high-tech blood product: pathogen-reduced, pooled plasma. It is a critical tool in the treatment of severe bleeding, coagulation disorders, and conditions like TTP. While the coding itself is just a single line on a claim, understanding the nuances of this code—from the meaning of “pooled” and “pathogen reduced” to the differences in inpatient and outpatient billing—is essential for medical billers, coders, and hospital financial teams.

Correct billing ensures that hospitals are appropriately reimbursed for these life-saving therapies, maintains compliance with federal programs, and supports accurate tracking of blood utilization. By connecting the physician’s order to the correct diagnosis and meticulously tracking the product from the blood bank to the patient’s bedside, healthcare organizations can master the billing for P9070.

Frequently Asked Questions (FAQ) About HCPCS Code P9070

Q: What does “pathogen reduced” mean for plasma?
A: It means the plasma has been treated with a process (like solvent/detergent or UV light) to inactivate viruses and other germs. This makes the blood supply safer by reducing the risk of transmitting infections to the patient.

Q: Is P9070 used for Fresh Frozen Plasma (FFP)?
A: No. P9070 is specifically for pooled, pathogen-reduced plasma. Standard Fresh Frozen Plasma (FFP) is typically billed with HCPCS code P9017. You must check the product label to be sure.

Q: Can a doctor’s office bill for P9070?
A: While it is possible in rare cases (if the practice has a supply of plasma and infuses it in the office), P9070 is almost exclusively billed by hospital facilities and blood banks due to the complexity of storing and handling blood products.

Q: Why does Medicare not pay separately for P9070 on an outpatient claim?
A: Medicare’s Hospital Outpatient Prospective Payment System (OPPS) “packages” many ancillary services and supplies into the payment for the primary service (like a clinic visit). The cost of the plasma is factored into the overall payment for the visit, rather than paid as a separate line item.

Q: What is the difference between billing for P9070 and billing for the transfusion?
A: P9070 is for the product (the bag of plasma). The transfusion itself is a medical procedure (setting up the IV, monitoring the patient) billed with a CPT code like 36430. You must bill both to account for the total cost of the service.

Additional Resource

For detailed rules on billing for blood and blood products under the Medicare program, you should refer to the Medicare Claims Processing Manual, Chapter 4. This manual outlines the specific requirements for Part B billing for blood and related services.
Link to Medicare Claims Processing Manual